Pharmaceutical Composition for Elevating Radiation-Sensitivity of Cancer Cells, Pharmaceutical Composition for Detecting Cancer Cells with Radiation-Sensitivity, and Detection Method Thereof

Abstract

The present invention relates to a pharmaceutical composition for elevating radiation-sensitivity of cancer cells, which comprises: a nanoparticle containing with a first element, which is iron, copper, or the combination thereof; and a pharmaceutically acceptable carrier, wherein the nanoparticle is a metal nanoparticle, an alloy nanoparticle, or a metal nanoparticle with core-shell structure. In addition, the present invention provides a detection method to detect radiation-sensitivity of the cancer cells through different modalities such as CT or MRI due to its native high CT number and magnetic property. Furthermore, the present invention provides a pharmaceutical composition for elevating radiation-sensitivity of the cancer cells through preferential uptake of the nanoparticle, in order to enhance the radiation-sensitivity of the cancer cells and improve the efficiency of radiation therapy to the cancer cells.

1 - 10 . (canceled) 
     
     
         11 . A method for increasing radiation-sensitivity of a cancer cell, comprising the steps of:
 adding a pharmaceutical composition to a cancer cell and culturing for a predetermined time,   wherein the pharmaceutical composition comprises: a nanoparticle consisting essentially of a first element and a second element; and a medical acceptable carrier;   wherein the first element is platinum, and the second element is at least one selected from the group consisting of: iron, cobalt, palladium, silver, nickel, and gadolinium; and   wherein the diameter of the nanoparticle is 3 nm to 12 nm.   
     
     
         12 . The method according to  claim 11 , wherein the nanoparticle is metal nanoparticle, alloy nanoparticle, or metal nanoparticle with a core-shell structure. 
     
     
         13 . The method according to  claim 11 , wherein the cancer cell is radiation resistant. 
     
     
         14 . The method according to  claim 11 , wherein the cancer cell is a solid state cancer cell. 
     
     
         15 . The method according to claim  1 , wherein the cancer cell is a lung cancer cell. 
     
     
         16 . The method according to  claim 11 , wherein the predetermined time is 24 hours. 
     
     
         17 . The method according to  claim 11 , further comprising the steps of: irradiating a predetermined radiation dosage of radiation on the cancer cell after adding the pharmaceutical composition to the cancer cell. 
     
     
         18 . The method according to  claim 17 , wherein the predetermined radiation dosage is 6 Gy.